Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News Marathon halts launch of Duchenne drug after price outcry Company says it will listen to concerns of patient advocates
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
